● Recruiting

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

Condition: Breast Cancer · HER2-low Breast Cancer · Metastatic Breast Cancer · Sponsor: Ana C Garrido-Castro, MD

PhasePhase 2

Planned participants357

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HER2-low or HER2-0) metastatic breast cancer. The names of the study drugs involved in this study are: * Datopotamab deruxtecan (a type of antibody drug conjugate) * Trastuzumab deruxtecan (a type of antibody drug conjugate)

This description comes directly from the study's public registry record.

Talk to the study team

Ana Garrido-Castro, MD · 617-632-3800 · ana_garrido-castro@dfci.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (11)

University of Alabama	Birmingham, Alabama, United States	Recruiting
University of San Francisco	San Francisco, California, United States	Recruiting
Yale University Cancer Center	New Haven, Connecticut, United States	Recruiting
Georgetown University Medical Center	Washington D.C., District of Columbia, United States	Recruiting
University of Chicago Medical Center	Chicago, Illinois, United States	Recruiting
Beth Israel Deaconess Medical Center	Boston, Massachusetts, United States	Recruiting
Dana-Farber Cancer Institute	Boston, Massachusetts, United States	Recruiting
Montefiore Einstein Comprehensive Cancer Center	The Bronx, New York, United States	Recruiting
University of North Carolina	Chapel Hill, North Carolina, United States	Recruiting
Vanderbilt Cancer Center	Nashville, Tennessee, United States	Recruiting
Baylor College of Medicine	Houston, Texas, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06533826